METHODS

- We analyzed Symphony medical and pharmacy claims from 2016 to 2021 and associated
- Disease activity prior to index treatment date: 12 months (naïve) or 3 months (experienced),
- We report HRU and costs (per-person-per-year [PPPY]) in US$ by initial treatment.

RESULTS

- Among ≥5040 patients with soHCM, the median age was 64 years and 55.9% were female (Table 1).
- Among patients treated with pharmacotherapy, 87.4% were prescribed monotherapy.
- Impressive differences in treatment, outpatient visits contributed to most overall costs.

CONCLUSIONS

- In this large, US based cohort of treatment-naïve patients with soHCM, initial therapy was most commonly BB or CCB monotherapy, but a substantial minority received BB+CCB combination therapy or invasive procedures.
- Unadjusted HRU and costs were high for most patients, but greater for those treated initially with BB+CCB combination therapy or invasive procedures.

REFERENCES


Disclosures

This study was funded by Cytokinetics, Incorporated. MB, SBH, D.J., SJ, DSNY, and RS: Employees of and own stock in Cytokinetics, Incorporated. SSen, JCB, EP, RR, XL, and JFN: No conflicts of interest to disclose.

Acknowledgments

Electronic support for the preparation of this poster was provided by Susan Tan, PhD, on behalf of Engage Scientific Solutions, Sydney, Australia, and was funded by Cytokinetics, Incorporated.

Abbreviations

BB, beta-blocker; CCB, calcium channel blocker; HCM, hypertrophic cardiomyopathy; HCRU, healthcare resource utilization; PPPY, per-person-per-year; soHCM, symptomatic obstructive hypertrophic cardiomyopathy; SRT, septal reduction therapy.